Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
31,889
archived clinical trials in
Blood Cancer

Assessing Compliance With Mercaptopurine Treatment in Younger Patients With Acute Lymphoblastic Leukemia in First Remission
A Comprehensive Approach to Improve Medication Adherence in Pediatric ALL
Status: Enrolling
Updated:  12/31/1969
Saint Joseph's Hospital/Children's Hospital-Tampa
mi
from
Tampa, FL
Assessing Compliance With Mercaptopurine Treatment in Younger Patients With Acute Lymphoblastic Leukemia in First Remission
A Comprehensive Approach to Improve Medication Adherence in Pediatric ALL
Status: Enrolling
Updated: 12/31/1969
Saint Joseph's Hospital/Children's Hospital-Tampa
mi
from
Tampa, FL
Click here to add this to my saved trials
Assessing Compliance With Mercaptopurine Treatment in Younger Patients With Acute Lymphoblastic Leukemia in First Remission
A Comprehensive Approach to Improve Medication Adherence in Pediatric ALL
Status: Enrolling
Updated:  12/31/1969
University of Hawaii Cancer Center
mi
from
Honolulu, HI
Assessing Compliance With Mercaptopurine Treatment in Younger Patients With Acute Lymphoblastic Leukemia in First Remission
A Comprehensive Approach to Improve Medication Adherence in Pediatric ALL
Status: Enrolling
Updated: 12/31/1969
University of Hawaii Cancer Center
mi
from
Honolulu, HI
Click here to add this to my saved trials
Assessing Compliance With Mercaptopurine Treatment in Younger Patients With Acute Lymphoblastic Leukemia in First Remission
A Comprehensive Approach to Improve Medication Adherence in Pediatric ALL
Status: Enrolling
Updated:  12/31/1969
Kapiolani Medical Center for Women and Children
mi
from
Honolulu, HI
Assessing Compliance With Mercaptopurine Treatment in Younger Patients With Acute Lymphoblastic Leukemia in First Remission
A Comprehensive Approach to Improve Medication Adherence in Pediatric ALL
Status: Enrolling
Updated: 12/31/1969
Kapiolani Medical Center for Women and Children
mi
from
Honolulu, HI
Click here to add this to my saved trials
Assessing Compliance With Mercaptopurine Treatment in Younger Patients With Acute Lymphoblastic Leukemia in First Remission
A Comprehensive Approach to Improve Medication Adherence in Pediatric ALL
Status: Enrolling
Updated:  12/31/1969
Advocate Children's Hospital, Park Ridge
mi
from
Park Ridge, IL
Assessing Compliance With Mercaptopurine Treatment in Younger Patients With Acute Lymphoblastic Leukemia in First Remission
A Comprehensive Approach to Improve Medication Adherence in Pediatric ALL
Status: Enrolling
Updated: 12/31/1969
Advocate Children's Hospital, Park Ridge
mi
from
Park Ridge, IL
Click here to add this to my saved trials
Assessing Compliance With Mercaptopurine Treatment in Younger Patients With Acute Lymphoblastic Leukemia in First Remission
A Comprehensive Approach to Improve Medication Adherence in Pediatric ALL
Status: Enrolling
Updated:  12/31/1969
Saint Vincent Hospital and Health Care Center
mi
from
Indianapolis, IN
Assessing Compliance With Mercaptopurine Treatment in Younger Patients With Acute Lymphoblastic Leukemia in First Remission
A Comprehensive Approach to Improve Medication Adherence in Pediatric ALL
Status: Enrolling
Updated: 12/31/1969
Saint Vincent Hospital and Health Care Center
mi
from
Indianapolis, IN
Click here to add this to my saved trials
Assessing Compliance With Mercaptopurine Treatment in Younger Patients With Acute Lymphoblastic Leukemia in First Remission
A Comprehensive Approach to Improve Medication Adherence in Pediatric ALL
Status: Enrolling
Updated:  12/31/1969
University of Iowa - Holden Comprehensive Cancer Center
mi
from
Iowa City, IA
Assessing Compliance With Mercaptopurine Treatment in Younger Patients With Acute Lymphoblastic Leukemia in First Remission
A Comprehensive Approach to Improve Medication Adherence in Pediatric ALL
Status: Enrolling
Updated: 12/31/1969
University of Iowa - Holden Comprehensive Cancer Center
mi
from
Iowa City, IA
Click here to add this to my saved trials
Assessing Compliance With Mercaptopurine Treatment in Younger Patients With Acute Lymphoblastic Leukemia in First Remission
A Comprehensive Approach to Improve Medication Adherence in Pediatric ALL
Status: Enrolling
Updated:  12/31/1969
Children's Hospital of New Orleans
mi
from
New Orleans, LA
Assessing Compliance With Mercaptopurine Treatment in Younger Patients With Acute Lymphoblastic Leukemia in First Remission
A Comprehensive Approach to Improve Medication Adherence in Pediatric ALL
Status: Enrolling
Updated: 12/31/1969
Children's Hospital of New Orleans
mi
from
New Orleans, LA
Click here to add this to my saved trials
Assessing Compliance With Mercaptopurine Treatment in Younger Patients With Acute Lymphoblastic Leukemia in First Remission
A Comprehensive Approach to Improve Medication Adherence in Pediatric ALL
Status: Enrolling
Updated:  12/31/1969
University of Minnesota, Masonic Cancer Center
mi
from
Minneapolis, MN
Assessing Compliance With Mercaptopurine Treatment in Younger Patients With Acute Lymphoblastic Leukemia in First Remission
A Comprehensive Approach to Improve Medication Adherence in Pediatric ALL
Status: Enrolling
Updated: 12/31/1969
University of Minnesota, Masonic Cancer Center
mi
from
Minneapolis, MN
Click here to add this to my saved trials
Assessing Compliance With Mercaptopurine Treatment in Younger Patients With Acute Lymphoblastic Leukemia in First Remission
A Comprehensive Approach to Improve Medication Adherence in Pediatric ALL
Status: Enrolling
Updated:  12/31/1969
Washington University School of Medicine
mi
from
Saint Louis, MO
Assessing Compliance With Mercaptopurine Treatment in Younger Patients With Acute Lymphoblastic Leukemia in First Remission
A Comprehensive Approach to Improve Medication Adherence in Pediatric ALL
Status: Enrolling
Updated: 12/31/1969
Washington University School of Medicine
mi
from
Saint Louis, MO
Click here to add this to my saved trials
Assessing Compliance With Mercaptopurine Treatment in Younger Patients With Acute Lymphoblastic Leukemia in First Remission
A Comprehensive Approach to Improve Medication Adherence in Pediatric ALL
Status: Enrolling
Updated:  12/31/1969
Mercy Hospital Saint Louis
mi
from
Saint Louis, MO
Assessing Compliance With Mercaptopurine Treatment in Younger Patients With Acute Lymphoblastic Leukemia in First Remission
A Comprehensive Approach to Improve Medication Adherence in Pediatric ALL
Status: Enrolling
Updated: 12/31/1969
Mercy Hospital Saint Louis
mi
from
Saint Louis, MO
Click here to add this to my saved trials
Assessing Compliance With Mercaptopurine Treatment in Younger Patients With Acute Lymphoblastic Leukemia in First Remission
A Comprehensive Approach to Improve Medication Adherence in Pediatric ALL
Status: Enrolling
Updated:  12/31/1969
University Medical Center of Southern Nevada
mi
from
Las Vegas, NV
Assessing Compliance With Mercaptopurine Treatment in Younger Patients With Acute Lymphoblastic Leukemia in First Remission
A Comprehensive Approach to Improve Medication Adherence in Pediatric ALL
Status: Enrolling
Updated: 12/31/1969
University Medical Center of Southern Nevada
mi
from
Las Vegas, NV
Click here to add this to my saved trials
Assessing Compliance With Mercaptopurine Treatment in Younger Patients With Acute Lymphoblastic Leukemia in First Remission
A Comprehensive Approach to Improve Medication Adherence in Pediatric ALL
Status: Enrolling
Updated:  12/31/1969
Morristown Medical Center
mi
from
Morristown, NJ
Assessing Compliance With Mercaptopurine Treatment in Younger Patients With Acute Lymphoblastic Leukemia in First Remission
A Comprehensive Approach to Improve Medication Adherence in Pediatric ALL
Status: Enrolling
Updated: 12/31/1969
Morristown Medical Center
mi
from
Morristown, NJ
Click here to add this to my saved trials
Assessing Compliance With Mercaptopurine Treatment in Younger Patients With Acute Lymphoblastic Leukemia in First Remission
A Comprehensive Approach to Improve Medication Adherence in Pediatric ALL
Status: Enrolling
Updated:  12/31/1969
Saint Peter's University Hospital
mi
from
New Brunswick, NJ
Assessing Compliance With Mercaptopurine Treatment in Younger Patients With Acute Lymphoblastic Leukemia in First Remission
A Comprehensive Approach to Improve Medication Adherence in Pediatric ALL
Status: Enrolling
Updated: 12/31/1969
Saint Peter's University Hospital
mi
from
New Brunswick, NJ
Click here to add this to my saved trials
Assessing Compliance With Mercaptopurine Treatment in Younger Patients With Acute Lymphoblastic Leukemia in First Remission
A Comprehensive Approach to Improve Medication Adherence in Pediatric ALL
Status: Enrolling
Updated:  12/31/1969
University of New Mexico Cancer Center
mi
from
Albuquerque, NM
Assessing Compliance With Mercaptopurine Treatment in Younger Patients With Acute Lymphoblastic Leukemia in First Remission
A Comprehensive Approach to Improve Medication Adherence in Pediatric ALL
Status: Enrolling
Updated: 12/31/1969
University of New Mexico Cancer Center
mi
from
Albuquerque, NM
Click here to add this to my saved trials
Assessing Compliance With Mercaptopurine Treatment in Younger Patients With Acute Lymphoblastic Leukemia in First Remission
A Comprehensive Approach to Improve Medication Adherence in Pediatric ALL
Status: Enrolling
Updated:  12/31/1969
Albany Medical Center
mi
from
Albany, NY
Assessing Compliance With Mercaptopurine Treatment in Younger Patients With Acute Lymphoblastic Leukemia in First Remission
A Comprehensive Approach to Improve Medication Adherence in Pediatric ALL
Status: Enrolling
Updated: 12/31/1969
Albany Medical Center
mi
from
Albany, NY
Click here to add this to my saved trials
Assessing Compliance With Mercaptopurine Treatment in Younger Patients With Acute Lymphoblastic Leukemia in First Remission
A Comprehensive Approach to Improve Medication Adherence in Pediatric ALL
Status: Enrolling
Updated:  12/31/1969
Montefiore Medical Center - Moses Campus
mi
from
Bronx, NY
Assessing Compliance With Mercaptopurine Treatment in Younger Patients With Acute Lymphoblastic Leukemia in First Remission
A Comprehensive Approach to Improve Medication Adherence in Pediatric ALL
Status: Enrolling
Updated: 12/31/1969
Montefiore Medical Center - Moses Campus
mi
from
Bronx, NY
Click here to add this to my saved trials
Assessing Compliance With Mercaptopurine Treatment in Younger Patients With Acute Lymphoblastic Leukemia in First Remission
A Comprehensive Approach to Improve Medication Adherence in Pediatric ALL
Status: Enrolling
Updated:  12/31/1969
Laura and Isaac Perlmutter Cancer Center @ NYU Langone
mi
from
New York, NY
Assessing Compliance With Mercaptopurine Treatment in Younger Patients With Acute Lymphoblastic Leukemia in First Remission
A Comprehensive Approach to Improve Medication Adherence in Pediatric ALL
Status: Enrolling
Updated: 12/31/1969
Laura and Isaac Perlmutter Cancer Center @ NYU Langone
mi
from
New York, NY
Click here to add this to my saved trials
Assessing Compliance With Mercaptopurine Treatment in Younger Patients With Acute Lymphoblastic Leukemia in First Remission
A Comprehensive Approach to Improve Medication Adherence in Pediatric ALL
Status: Enrolling
Updated:  12/31/1969
Columbia University Herbert Irving Cancer Center
mi
from
New York, NY
Assessing Compliance With Mercaptopurine Treatment in Younger Patients With Acute Lymphoblastic Leukemia in First Remission
A Comprehensive Approach to Improve Medication Adherence in Pediatric ALL
Status: Enrolling
Updated: 12/31/1969
Columbia University Herbert Irving Cancer Center
mi
from
New York, NY
Click here to add this to my saved trials
Assessing Compliance With Mercaptopurine Treatment in Younger Patients With Acute Lymphoblastic Leukemia in First Remission
A Comprehensive Approach to Improve Medication Adherence in Pediatric ALL
Status: Enrolling
Updated:  12/31/1969
Oregon Health and Science University
mi
from
Portland, OR
Assessing Compliance With Mercaptopurine Treatment in Younger Patients With Acute Lymphoblastic Leukemia in First Remission
A Comprehensive Approach to Improve Medication Adherence in Pediatric ALL
Status: Enrolling
Updated: 12/31/1969
Oregon Health and Science University
mi
from
Portland, OR
Click here to add this to my saved trials
Assessing Compliance With Mercaptopurine Treatment in Younger Patients With Acute Lymphoblastic Leukemia in First Remission
A Comprehensive Approach to Improve Medication Adherence in Pediatric ALL
Status: Enrolling
Updated:  12/31/1969
Geisinger Medical Center
mi
from
Danville, PA
Assessing Compliance With Mercaptopurine Treatment in Younger Patients With Acute Lymphoblastic Leukemia in First Remission
A Comprehensive Approach to Improve Medication Adherence in Pediatric ALL
Status: Enrolling
Updated: 12/31/1969
Geisinger Medical Center
mi
from
Danville, PA
Click here to add this to my saved trials
Assessing Compliance With Mercaptopurine Treatment in Younger Patients With Acute Lymphoblastic Leukemia in First Remission
A Comprehensive Approach to Improve Medication Adherence in Pediatric ALL
Status: Enrolling
Updated:  12/31/1969
BI-LO Charities Children's Cancer Center
mi
from
Greenville, SC
Assessing Compliance With Mercaptopurine Treatment in Younger Patients With Acute Lymphoblastic Leukemia in First Remission
A Comprehensive Approach to Improve Medication Adherence in Pediatric ALL
Status: Enrolling
Updated: 12/31/1969
BI-LO Charities Children's Cancer Center
mi
from
Greenville, SC
Click here to add this to my saved trials
Assessing Compliance With Mercaptopurine Treatment in Younger Patients With Acute Lymphoblastic Leukemia in First Remission
A Comprehensive Approach to Improve Medication Adherence in Pediatric ALL
Status: Enrolling
Updated:  12/31/1969
East Tennessee Children's Hospital
mi
from
Knoxville, TN
Assessing Compliance With Mercaptopurine Treatment in Younger Patients With Acute Lymphoblastic Leukemia in First Remission
A Comprehensive Approach to Improve Medication Adherence in Pediatric ALL
Status: Enrolling
Updated: 12/31/1969
East Tennessee Children's Hospital
mi
from
Knoxville, TN
Click here to add this to my saved trials
Assessing Compliance With Mercaptopurine Treatment in Younger Patients With Acute Lymphoblastic Leukemia in First Remission
A Comprehensive Approach to Improve Medication Adherence in Pediatric ALL
Status: Enrolling
Updated:  12/31/1969
UT Southwestern/Simmons Cancer Center-Dallas
mi
from
Dallas, TX
Assessing Compliance With Mercaptopurine Treatment in Younger Patients With Acute Lymphoblastic Leukemia in First Remission
A Comprehensive Approach to Improve Medication Adherence in Pediatric ALL
Status: Enrolling
Updated: 12/31/1969
UT Southwestern/Simmons Cancer Center-Dallas
mi
from
Dallas, TX
Click here to add this to my saved trials
Assessing Compliance With Mercaptopurine Treatment in Younger Patients With Acute Lymphoblastic Leukemia in First Remission
A Comprehensive Approach to Improve Medication Adherence in Pediatric ALL
Status: Enrolling
Updated:  12/31/1969
Cook Children's Medical Center
mi
from
Fort Worth, TX
Assessing Compliance With Mercaptopurine Treatment in Younger Patients With Acute Lymphoblastic Leukemia in First Remission
A Comprehensive Approach to Improve Medication Adherence in Pediatric ALL
Status: Enrolling
Updated: 12/31/1969
Cook Children's Medical Center
mi
from
Fort Worth, TX
Click here to add this to my saved trials
Assessing Compliance With Mercaptopurine Treatment in Younger Patients With Acute Lymphoblastic Leukemia in First Remission
A Comprehensive Approach to Improve Medication Adherence in Pediatric ALL
Status: Enrolling
Updated:  12/31/1969
Baylor College of Medicine/Dan L Duncan Comprehensive Cancer Center
mi
from
Houston, TX
Assessing Compliance With Mercaptopurine Treatment in Younger Patients With Acute Lymphoblastic Leukemia in First Remission
A Comprehensive Approach to Improve Medication Adherence in Pediatric ALL
Status: Enrolling
Updated: 12/31/1969
Baylor College of Medicine/Dan L Duncan Comprehensive Cancer Center
mi
from
Houston, TX
Click here to add this to my saved trials
Assessing Compliance With Mercaptopurine Treatment in Younger Patients With Acute Lymphoblastic Leukemia in First Remission
A Comprehensive Approach to Improve Medication Adherence in Pediatric ALL
Status: Enrolling
Updated:  12/31/1969
Vannie Cook Children's Clinic
mi
from
McAllen, TX
Assessing Compliance With Mercaptopurine Treatment in Younger Patients With Acute Lymphoblastic Leukemia in First Remission
A Comprehensive Approach to Improve Medication Adherence in Pediatric ALL
Status: Enrolling
Updated: 12/31/1969
Vannie Cook Children's Clinic
mi
from
McAllen, TX
Click here to add this to my saved trials
Assessing Compliance With Mercaptopurine Treatment in Younger Patients With Acute Lymphoblastic Leukemia in First Remission
A Comprehensive Approach to Improve Medication Adherence in Pediatric ALL
Status: Enrolling
Updated:  12/31/1969
Virginia Commonwealth University Massey Cancer Center
mi
from
Richmond, VA
Assessing Compliance With Mercaptopurine Treatment in Younger Patients With Acute Lymphoblastic Leukemia in First Remission
A Comprehensive Approach to Improve Medication Adherence in Pediatric ALL
Status: Enrolling
Updated: 12/31/1969
Virginia Commonwealth University Massey Cancer Center
mi
from
Richmond, VA
Click here to add this to my saved trials
Assessing Compliance With Mercaptopurine Treatment in Younger Patients With Acute Lymphoblastic Leukemia in First Remission
A Comprehensive Approach to Improve Medication Adherence in Pediatric ALL
Status: Enrolling
Updated:  12/31/1969
Madigan Army Medical Center
mi
from
Tacoma, WA
Assessing Compliance With Mercaptopurine Treatment in Younger Patients With Acute Lymphoblastic Leukemia in First Remission
A Comprehensive Approach to Improve Medication Adherence in Pediatric ALL
Status: Enrolling
Updated: 12/31/1969
Madigan Army Medical Center
mi
from
Tacoma, WA
Click here to add this to my saved trials
Assessing Compliance With Mercaptopurine Treatment in Younger Patients With Acute Lymphoblastic Leukemia in First Remission
A Comprehensive Approach to Improve Medication Adherence in Pediatric ALL
Status: Enrolling
Updated:  12/31/1969
Saint Vincent Hospital Cancer Center Green Bay
mi
from
Green Bay, WI
Assessing Compliance With Mercaptopurine Treatment in Younger Patients With Acute Lymphoblastic Leukemia in First Remission
A Comprehensive Approach to Improve Medication Adherence in Pediatric ALL
Status: Enrolling
Updated: 12/31/1969
Saint Vincent Hospital Cancer Center Green Bay
mi
from
Green Bay, WI
Click here to add this to my saved trials
Assessing Compliance With Mercaptopurine Treatment in Younger Patients With Acute Lymphoblastic Leukemia in First Remission
A Comprehensive Approach to Improve Medication Adherence in Pediatric ALL
Status: Enrolling
Updated:  12/31/1969
Marshfield Clinic
mi
from
Marshfield, WI
Assessing Compliance With Mercaptopurine Treatment in Younger Patients With Acute Lymphoblastic Leukemia in First Remission
A Comprehensive Approach to Improve Medication Adherence in Pediatric ALL
Status: Enrolling
Updated: 12/31/1969
Marshfield Clinic
mi
from
Marshfield, WI
Click here to add this to my saved trials
Assessing Compliance With Mercaptopurine Treatment in Younger Patients With Acute Lymphoblastic Leukemia in First Remission
A Comprehensive Approach to Improve Medication Adherence in Pediatric ALL
Status: Enrolling
Updated:  12/31/1969
San Jorge Children's Hospital
mi
from
San Juan,
Assessing Compliance With Mercaptopurine Treatment in Younger Patients With Acute Lymphoblastic Leukemia in First Remission
A Comprehensive Approach to Improve Medication Adherence in Pediatric ALL
Status: Enrolling
Updated: 12/31/1969
San Jorge Children's Hospital
mi
from
San Juan,
Click here to add this to my saved trials
Assessing Compliance With Mercaptopurine Treatment in Younger Patients With Acute Lymphoblastic Leukemia in First Remission
A Comprehensive Approach to Improve Medication Adherence in Pediatric ALL
Status: Enrolling
Updated:  12/31/1969
Ascension Saint John Hospital
mi
from
Detroit, MI
Assessing Compliance With Mercaptopurine Treatment in Younger Patients With Acute Lymphoblastic Leukemia in First Remission
A Comprehensive Approach to Improve Medication Adherence in Pediatric ALL
Status: Enrolling
Updated: 12/31/1969
Ascension Saint John Hospital
mi
from
Detroit, MI
Click here to add this to my saved trials
Assessing Compliance With Mercaptopurine Treatment in Younger Patients With Acute Lymphoblastic Leukemia in First Remission
A Comprehensive Approach to Improve Medication Adherence in Pediatric ALL
Status: Enrolling
Updated:  12/31/1969
Alliance for Childhood Diseases/Cure 4 the Kids Foundation
mi
from
Las Vegas, NV
Assessing Compliance With Mercaptopurine Treatment in Younger Patients With Acute Lymphoblastic Leukemia in First Remission
A Comprehensive Approach to Improve Medication Adherence in Pediatric ALL
Status: Enrolling
Updated: 12/31/1969
Alliance for Childhood Diseases/Cure 4 the Kids Foundation
mi
from
Las Vegas, NV
Click here to add this to my saved trials
Testing a Spanish Version of a Patient Toxicity Questionnaire
Spanish Translation and Linguistic Validation of the Patient- Reported Outcomes Version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE)
Status: Enrolling
Updated:  12/31/1969
National Cancer Institute , 9000 Rockville Pike
mi
from
Bethesda, MD
Testing a Spanish Version of a Patient Toxicity Questionnaire
Spanish Translation and Linguistic Validation of the Patient- Reported Outcomes Version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE)
Status: Enrolling
Updated: 12/31/1969
National Cancer Institute , 9000 Rockville Pike
mi
from
Bethesda, MD
Click here to add this to my saved trials
Symptom-Adapted Physical Activity Intervention in Minimizing Physical Function Decline in Older Patients With Acute Myeloid Leukemia Undergoing Chemotherapy
Minimizing Physical Function Decline in Older Adults Receiving Chemotherapy
Status: Enrolling
Updated:  12/31/1969
Wake Forest University Health Sciences
mi
from
Winston-Salem, NC
Symptom-Adapted Physical Activity Intervention in Minimizing Physical Function Decline in Older Patients With Acute Myeloid Leukemia Undergoing Chemotherapy
Minimizing Physical Function Decline in Older Adults Receiving Chemotherapy
Status: Enrolling
Updated: 12/31/1969
Wake Forest University Health Sciences
mi
from
Winston-Salem, NC
Click here to add this to my saved trials
Phase 2 Study of the Combination of Bruton's Tyrosine Kinase Inhibitor PCI-32765 and Rituximab in High-Risk Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma Patients
A Phase 2 Study of the Combination of the Bruton's Tyrosine Kinase Inhibitor PCI-32765 and Rituximab in High-Risk Chronic Lymphocytic Leukemia (CLL) and Small Lymphocytic Lymphoma (SLL) Patients
Status: Enrolling
Updated:  12/31/1969
University of Texas M.D. Anderson Cancer Center
mi
from
Houston, TX
Phase 2 Study of the Combination of Bruton's Tyrosine Kinase Inhibitor PCI-32765 and Rituximab in High-Risk Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma Patients
A Phase 2 Study of the Combination of the Bruton's Tyrosine Kinase Inhibitor PCI-32765 and Rituximab in High-Risk Chronic Lymphocytic Leukemia (CLL) and Small Lymphocytic Lymphoma (SLL) Patients
Status: Enrolling
Updated: 12/31/1969
University of Texas M.D. Anderson Cancer Center
mi
from
Houston, TX
Click here to add this to my saved trials
Phase II Study of Crenolanib in Subjects With Relapsed/Refractory AML With FLT3 Activating Mutations
A Phase II Study of Crenolanib Besylate in Subjects With Relapsed/Refractory Acute Myeloid Leukemia With FLT3 Activating Mutations
Status: Enrolling
Updated:  12/31/1969
University of Texas Southwestern Medical Center
mi
from
Dallas, TX
Phase II Study of Crenolanib in Subjects With Relapsed/Refractory AML With FLT3 Activating Mutations
A Phase II Study of Crenolanib Besylate in Subjects With Relapsed/Refractory Acute Myeloid Leukemia With FLT3 Activating Mutations
Status: Enrolling
Updated: 12/31/1969
University of Texas Southwestern Medical Center
mi
from
Dallas, TX
Click here to add this to my saved trials
Azacitidine With or Without Lenalidomide or Vorinostat in Treating Patients With Higher-Risk Myelodysplastic Syndromes or Chronic Myelomonocytic Leukemia
A Randomized Phase II/III Study of Azacitidine in Combination With Lenalidomide (NSC-703813) vs. Azacitidine Alone vs. Azacitidine in Combination With Vorinostat (NSC-701852) for Higher-Risk Myelodysplastic Syndromes (MDS) and Chronic Myelomonocytic Leukemia (CMML)
Status: Enrolling
Updated:  12/31/1969
Mayo Clinic Arizona
mi
from
Scottsdale, AZ
Azacitidine With or Without Lenalidomide or Vorinostat in Treating Patients With Higher-Risk Myelodysplastic Syndromes or Chronic Myelomonocytic Leukemia
A Randomized Phase II/III Study of Azacitidine in Combination With Lenalidomide (NSC-703813) vs. Azacitidine Alone vs. Azacitidine in Combination With Vorinostat (NSC-701852) for Higher-Risk Myelodysplastic Syndromes (MDS) and Chronic Myelomonocytic Leukemia (CMML)
Status: Enrolling
Updated: 12/31/1969
Mayo Clinic Arizona
mi
from
Scottsdale, AZ
Click here to add this to my saved trials
Azacitidine With or Without Lenalidomide or Vorinostat in Treating Patients With Higher-Risk Myelodysplastic Syndromes or Chronic Myelomonocytic Leukemia
A Randomized Phase II/III Study of Azacitidine in Combination With Lenalidomide (NSC-703813) vs. Azacitidine Alone vs. Azacitidine in Combination With Vorinostat (NSC-701852) for Higher-Risk Myelodysplastic Syndromes (MDS) and Chronic Myelomonocytic Leukemia (CMML)
Status: Enrolling
Updated:  12/31/1969
Veteran's Administration Medical Center
mi
from
Little Rock, AR
Azacitidine With or Without Lenalidomide or Vorinostat in Treating Patients With Higher-Risk Myelodysplastic Syndromes or Chronic Myelomonocytic Leukemia
A Randomized Phase II/III Study of Azacitidine in Combination With Lenalidomide (NSC-703813) vs. Azacitidine Alone vs. Azacitidine in Combination With Vorinostat (NSC-701852) for Higher-Risk Myelodysplastic Syndromes (MDS) and Chronic Myelomonocytic Leukemia (CMML)
Status: Enrolling
Updated: 12/31/1969
Veteran's Administration Medical Center
mi
from
Little Rock, AR
Click here to add this to my saved trials
Azacitidine With or Without Lenalidomide or Vorinostat in Treating Patients With Higher-Risk Myelodysplastic Syndromes or Chronic Myelomonocytic Leukemia
A Randomized Phase II/III Study of Azacitidine in Combination With Lenalidomide (NSC-703813) vs. Azacitidine Alone vs. Azacitidine in Combination With Vorinostat (NSC-701852) for Higher-Risk Myelodysplastic Syndromes (MDS) and Chronic Myelomonocytic Leukemia (CMML)
Status: Enrolling
Updated:  12/31/1969
Kaiser Permanente Deer Valley Medical Center
mi
from
Antioch, CA
Azacitidine With or Without Lenalidomide or Vorinostat in Treating Patients With Higher-Risk Myelodysplastic Syndromes or Chronic Myelomonocytic Leukemia
A Randomized Phase II/III Study of Azacitidine in Combination With Lenalidomide (NSC-703813) vs. Azacitidine Alone vs. Azacitidine in Combination With Vorinostat (NSC-701852) for Higher-Risk Myelodysplastic Syndromes (MDS) and Chronic Myelomonocytic Leukemia (CMML)
Status: Enrolling
Updated: 12/31/1969
Kaiser Permanente Deer Valley Medical Center
mi
from
Antioch, CA
Click here to add this to my saved trials
Azacitidine With or Without Lenalidomide or Vorinostat in Treating Patients With Higher-Risk Myelodysplastic Syndromes or Chronic Myelomonocytic Leukemia
A Randomized Phase II/III Study of Azacitidine in Combination With Lenalidomide (NSC-703813) vs. Azacitidine Alone vs. Azacitidine in Combination With Vorinostat (NSC-701852) for Higher-Risk Myelodysplastic Syndromes (MDS) and Chronic Myelomonocytic Leukemia (CMML)
Status: Enrolling
Updated:  12/31/1969
Kaiser Permanente-Richmond
mi
from
Richmond, CA
Azacitidine With or Without Lenalidomide or Vorinostat in Treating Patients With Higher-Risk Myelodysplastic Syndromes or Chronic Myelomonocytic Leukemia
A Randomized Phase II/III Study of Azacitidine in Combination With Lenalidomide (NSC-703813) vs. Azacitidine Alone vs. Azacitidine in Combination With Vorinostat (NSC-701852) for Higher-Risk Myelodysplastic Syndromes (MDS) and Chronic Myelomonocytic Leukemia (CMML)
Status: Enrolling
Updated: 12/31/1969
Kaiser Permanente-Richmond
mi
from
Richmond, CA
Click here to add this to my saved trials
Azacitidine With or Without Lenalidomide or Vorinostat in Treating Patients With Higher-Risk Myelodysplastic Syndromes or Chronic Myelomonocytic Leukemia
A Randomized Phase II/III Study of Azacitidine in Combination With Lenalidomide (NSC-703813) vs. Azacitidine Alone vs. Azacitidine in Combination With Vorinostat (NSC-701852) for Higher-Risk Myelodysplastic Syndromes (MDS) and Chronic Myelomonocytic Leukemia (CMML)
Status: Enrolling
Updated:  12/31/1969
Kaiser Permanente - Sacramento
mi
from
Sacramento, CA
Azacitidine With or Without Lenalidomide or Vorinostat in Treating Patients With Higher-Risk Myelodysplastic Syndromes or Chronic Myelomonocytic Leukemia
A Randomized Phase II/III Study of Azacitidine in Combination With Lenalidomide (NSC-703813) vs. Azacitidine Alone vs. Azacitidine in Combination With Vorinostat (NSC-701852) for Higher-Risk Myelodysplastic Syndromes (MDS) and Chronic Myelomonocytic Leukemia (CMML)
Status: Enrolling
Updated: 12/31/1969
Kaiser Permanente - Sacramento
mi
from
Sacramento, CA
Click here to add this to my saved trials
Azacitidine With or Without Lenalidomide or Vorinostat in Treating Patients With Higher-Risk Myelodysplastic Syndromes or Chronic Myelomonocytic Leukemia
A Randomized Phase II/III Study of Azacitidine in Combination With Lenalidomide (NSC-703813) vs. Azacitidine Alone vs. Azacitidine in Combination With Vorinostat (NSC-701852) for Higher-Risk Myelodysplastic Syndromes (MDS) and Chronic Myelomonocytic Leukemia (CMML)
Status: Enrolling
Updated:  12/31/1969
Kaiser Permanente-South Sacramento
mi
from
Sacramento, CA
Azacitidine With or Without Lenalidomide or Vorinostat in Treating Patients With Higher-Risk Myelodysplastic Syndromes or Chronic Myelomonocytic Leukemia
A Randomized Phase II/III Study of Azacitidine in Combination With Lenalidomide (NSC-703813) vs. Azacitidine Alone vs. Azacitidine in Combination With Vorinostat (NSC-701852) for Higher-Risk Myelodysplastic Syndromes (MDS) and Chronic Myelomonocytic Leukemia (CMML)
Status: Enrolling
Updated: 12/31/1969
Kaiser Permanente-South Sacramento
mi
from
Sacramento, CA
Click here to add this to my saved trials
Azacitidine With or Without Lenalidomide or Vorinostat in Treating Patients With Higher-Risk Myelodysplastic Syndromes or Chronic Myelomonocytic Leukemia
A Randomized Phase II/III Study of Azacitidine in Combination With Lenalidomide (NSC-703813) vs. Azacitidine Alone vs. Azacitidine in Combination With Vorinostat (NSC-701852) for Higher-Risk Myelodysplastic Syndromes (MDS) and Chronic Myelomonocytic Leukemia (CMML)
Status: Enrolling
Updated:  12/31/1969
Kaiser Permanente-San Francisco
mi
from
San Francisco, CA
Azacitidine With or Without Lenalidomide or Vorinostat in Treating Patients With Higher-Risk Myelodysplastic Syndromes or Chronic Myelomonocytic Leukemia
A Randomized Phase II/III Study of Azacitidine in Combination With Lenalidomide (NSC-703813) vs. Azacitidine Alone vs. Azacitidine in Combination With Vorinostat (NSC-701852) for Higher-Risk Myelodysplastic Syndromes (MDS) and Chronic Myelomonocytic Leukemia (CMML)
Status: Enrolling
Updated: 12/31/1969
Kaiser Permanente-San Francisco
mi
from
San Francisco, CA
Click here to add this to my saved trials
Azacitidine With or Without Lenalidomide or Vorinostat in Treating Patients With Higher-Risk Myelodysplastic Syndromes or Chronic Myelomonocytic Leukemia
A Randomized Phase II/III Study of Azacitidine in Combination With Lenalidomide (NSC-703813) vs. Azacitidine Alone vs. Azacitidine in Combination With Vorinostat (NSC-701852) for Higher-Risk Myelodysplastic Syndromes (MDS) and Chronic Myelomonocytic Leukemia (CMML)
Status: Enrolling
Updated:  12/31/1969
Kaiser Permanente-Santa Teresa-San Jose
mi
from
San Jose, CA
Azacitidine With or Without Lenalidomide or Vorinostat in Treating Patients With Higher-Risk Myelodysplastic Syndromes or Chronic Myelomonocytic Leukemia
A Randomized Phase II/III Study of Azacitidine in Combination With Lenalidomide (NSC-703813) vs. Azacitidine Alone vs. Azacitidine in Combination With Vorinostat (NSC-701852) for Higher-Risk Myelodysplastic Syndromes (MDS) and Chronic Myelomonocytic Leukemia (CMML)
Status: Enrolling
Updated: 12/31/1969
Kaiser Permanente-Santa Teresa-San Jose
mi
from
San Jose, CA
Click here to add this to my saved trials
Azacitidine With or Without Lenalidomide or Vorinostat in Treating Patients With Higher-Risk Myelodysplastic Syndromes or Chronic Myelomonocytic Leukemia
A Randomized Phase II/III Study of Azacitidine in Combination With Lenalidomide (NSC-703813) vs. Azacitidine Alone vs. Azacitidine in Combination With Vorinostat (NSC-701852) for Higher-Risk Myelodysplastic Syndromes (MDS) and Chronic Myelomonocytic Leukemia (CMML)
Status: Enrolling
Updated:  12/31/1969
Kaiser Permanente San Rafael
mi
from
San Rafael, CA
Azacitidine With or Without Lenalidomide or Vorinostat in Treating Patients With Higher-Risk Myelodysplastic Syndromes or Chronic Myelomonocytic Leukemia
A Randomized Phase II/III Study of Azacitidine in Combination With Lenalidomide (NSC-703813) vs. Azacitidine Alone vs. Azacitidine in Combination With Vorinostat (NSC-701852) for Higher-Risk Myelodysplastic Syndromes (MDS) and Chronic Myelomonocytic Leukemia (CMML)
Status: Enrolling
Updated: 12/31/1969
Kaiser Permanente San Rafael
mi
from
San Rafael, CA
Click here to add this to my saved trials
Azacitidine With or Without Lenalidomide or Vorinostat in Treating Patients With Higher-Risk Myelodysplastic Syndromes or Chronic Myelomonocytic Leukemia
A Randomized Phase II/III Study of Azacitidine in Combination With Lenalidomide (NSC-703813) vs. Azacitidine Alone vs. Azacitidine in Combination With Vorinostat (NSC-701852) for Higher-Risk Myelodysplastic Syndromes (MDS) and Chronic Myelomonocytic Leukemia (CMML)
Status: Enrolling
Updated:  12/31/1969
Kaiser Permanente Santa Clara Medical Center and Medical Offices
mi
from
Santa Clara, CA
Azacitidine With or Without Lenalidomide or Vorinostat in Treating Patients With Higher-Risk Myelodysplastic Syndromes or Chronic Myelomonocytic Leukemia
A Randomized Phase II/III Study of Azacitidine in Combination With Lenalidomide (NSC-703813) vs. Azacitidine Alone vs. Azacitidine in Combination With Vorinostat (NSC-701852) for Higher-Risk Myelodysplastic Syndromes (MDS) and Chronic Myelomonocytic Leukemia (CMML)
Status: Enrolling
Updated: 12/31/1969
Kaiser Permanente Santa Clara Medical Center and Medical Offices
mi
from
Santa Clara, CA
Click here to add this to my saved trials
Azacitidine With or Without Lenalidomide or Vorinostat in Treating Patients With Higher-Risk Myelodysplastic Syndromes or Chronic Myelomonocytic Leukemia
A Randomized Phase II/III Study of Azacitidine in Combination With Lenalidomide (NSC-703813) vs. Azacitidine Alone vs. Azacitidine in Combination With Vorinostat (NSC-701852) for Higher-Risk Myelodysplastic Syndromes (MDS) and Chronic Myelomonocytic Leukemia (CMML)
Status: Enrolling
Updated:  12/31/1969
Kaiser Permanente-Santa Rosa
mi
from
Santa Rosa, CA
Azacitidine With or Without Lenalidomide or Vorinostat in Treating Patients With Higher-Risk Myelodysplastic Syndromes or Chronic Myelomonocytic Leukemia
A Randomized Phase II/III Study of Azacitidine in Combination With Lenalidomide (NSC-703813) vs. Azacitidine Alone vs. Azacitidine in Combination With Vorinostat (NSC-701852) for Higher-Risk Myelodysplastic Syndromes (MDS) and Chronic Myelomonocytic Leukemia (CMML)
Status: Enrolling
Updated: 12/31/1969
Kaiser Permanente-Santa Rosa
mi
from
Santa Rosa, CA
Click here to add this to my saved trials
Azacitidine With or Without Lenalidomide or Vorinostat in Treating Patients With Higher-Risk Myelodysplastic Syndromes or Chronic Myelomonocytic Leukemia
A Randomized Phase II/III Study of Azacitidine in Combination With Lenalidomide (NSC-703813) vs. Azacitidine Alone vs. Azacitidine in Combination With Vorinostat (NSC-701852) for Higher-Risk Myelodysplastic Syndromes (MDS) and Chronic Myelomonocytic Leukemia (CMML)
Status: Enrolling
Updated:  12/31/1969
Sutter Pacific Medical Foundation
mi
from
Santa Rosa, CA
Azacitidine With or Without Lenalidomide or Vorinostat in Treating Patients With Higher-Risk Myelodysplastic Syndromes or Chronic Myelomonocytic Leukemia
A Randomized Phase II/III Study of Azacitidine in Combination With Lenalidomide (NSC-703813) vs. Azacitidine Alone vs. Azacitidine in Combination With Vorinostat (NSC-701852) for Higher-Risk Myelodysplastic Syndromes (MDS) and Chronic Myelomonocytic Leukemia (CMML)
Status: Enrolling
Updated: 12/31/1969
Sutter Pacific Medical Foundation
mi
from
Santa Rosa, CA
Click here to add this to my saved trials
Azacitidine With or Without Lenalidomide or Vorinostat in Treating Patients With Higher-Risk Myelodysplastic Syndromes or Chronic Myelomonocytic Leukemia
A Randomized Phase II/III Study of Azacitidine in Combination With Lenalidomide (NSC-703813) vs. Azacitidine Alone vs. Azacitidine in Combination With Vorinostat (NSC-701852) for Higher-Risk Myelodysplastic Syndromes (MDS) and Chronic Myelomonocytic Leukemia (CMML)
Status: Enrolling
Updated:  12/31/1969
Kaiser Permanente-South San Francisco
mi
from
South San Francisco, CA
Azacitidine With or Without Lenalidomide or Vorinostat in Treating Patients With Higher-Risk Myelodysplastic Syndromes or Chronic Myelomonocytic Leukemia
A Randomized Phase II/III Study of Azacitidine in Combination With Lenalidomide (NSC-703813) vs. Azacitidine Alone vs. Azacitidine in Combination With Vorinostat (NSC-701852) for Higher-Risk Myelodysplastic Syndromes (MDS) and Chronic Myelomonocytic Leukemia (CMML)
Status: Enrolling
Updated: 12/31/1969
Kaiser Permanente-South San Francisco
mi
from
South San Francisco, CA
Click here to add this to my saved trials